Hikma Pharmaceuticals Plc Hikma agrees to acquire EIMC United Pharmaceutical
September 08 2015 - 2:01AM
RNS Non-Regulatory
TIDMHIK
Hikma Pharmaceuticals Plc
08 September 2015
PRESS RELEASE
Hikma agrees to acquire EIMC United Pharmaceuticals,
strengthening its position in the large and fast growing Egyptian
market
London, 8 September 2015 - Hikma Pharmaceuticals PLC ("Hikma")
(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing
multinational pharmaceutical group, today announces that it has
agreed to acquire 98.09% of the share capital of EIMC United
Pharmaceuticals ("EUP") from a consortium of shareholders.
EUP is a pharmaceutical manufacturing company specialising in
oncology products. The acquisition of EUP:
-- Strengthens Hikma's position in the large and fast growing Egyptian market
-- Brings an attractive portfolio and pipeline in the key
strategic areas of oncology and injectables, with the potential to
add around 50 products by 2020
-- Adds a manufacturing facility in Egypt, with both oral and injectable lines
-- Leverages Hikma's established market position in Egypt and strong sales and marketing team
The Egyptian pharmaceutical market is one of the three major
pharmaceutical markets in the Middle East and North Africa
("MENA"). According to IMS Health,(1) the private retail market is
valued at around $3.8 billion and grew by 8.3% in the twelve months
to June 2015. With a population of approximately 87(2) million
people, the Egyptian market offers excellent growth opportunities.
Hikma Egypt is currently the eleventh largest pharmaceutical
manufacturer in Egypt, with an estimated market share of
2.0%.(1)
Commenting on the transaction, Mazen Darwazah, Hikma Vice
Chairman and CEO of MENA said, "Egypt is a very important market
for Hikma and we have been rapidly growing our business there over
the last few years. Acquiring EUP will further strengthen our
market position and be a key driver of future growth. Across the
Group, expansion in the areas of oncology and injectables are key
strategic priorities and I am very pleased to be developing our
capabilities in the MENA region."
HC Securities and Investment, the Cairo-based investment bank,
acted as advisor to Hikma on this acquisition. The transaction is
subject to certain regulatory approvals and closing conditions.
----- ENDS -----
Enquiries
Hikma Pharmaceuticals PLC
Susan Ringdal, VP Corporate Strategy and Investor Relations +44
(0)20 7399 2760/ +44 7776 477050
Lucinda Baker, Deputy Director of Investor Relations +44 (0)20
7399 2765/ +44 7818 060211
Zeena Murad, Investor Relations Manager +44 (0)20 7399 2768/ +44
7771 665277
FTI Consulting +44 (0)20 7831 3113
Ben Atwell / Matthew Cole
About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational
pharmaceutical group focused on developing, manufacturing and
marketing a broad range of both branded and non-branded generic and
in-licensed products. Hikma's operations are conducted through
three businesses: "Branded", "Injectables" and "Generics" based
principally in the Middle East and North Africa ("MENA") region,
where it is a market leader, the United States and Europe. In 2014,
Hikma achieved revenues of $1,489 million and profit attributable
to shareholders of $299 million.
1 IMS Health (local country data) MAT June 2015
2 The CIA World Factbook, July 2014 estimate
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALRMFTMBBMBJA
(END) Dow Jones Newswires
September 08, 2015 02:01 ET (06:01 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024